---
{"dg-publish":true,"permalink":"/0-inbox/renal-disorders-summary/","tags":["Summary"],"created":"2024-02-04T19:46:48.748+07:00","updated":"2025-10-06T19:51:37.275+07:00"}
---

**Author:** ‡∏û‡∏≠‡∏à‡∏≠ c91 rx80 üíò
**Publish Date:**
**Note:** ‡πÇ‡∏õ‡∏£‡∏î‡∏≠‡πà‡∏≤‡∏ô‡∏ï‡∏≤‡∏°‡∏®‡∏£‡∏±‡∏ó‡∏ò‡∏≤ ‡πÅ‡∏•‡∏∞‡∏≠‡∏¢‡πà‡∏≤‡πÇ‡∏õ‡∏£‡∏î‡∏ß‡πà‡∏≤‡∏Å‡∏±‡∏ô‡∏ñ‡πâ‡∏≤‡∏°‡∏µ‡∏™‡∏£‡∏∏‡∏õ‡∏ú‡∏¥‡∏î; summary for PC1 only
[[0 Inbox/Fluid and Electrolyte Disorder\|Fluid and Electrolyte Disorder]] ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ó‡∏≥‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏Ç‡∏µ‡πâ‡πÄ‡∏Å‡∏µ‡∏¢‡∏à

# Note from QBank Practice
- [x] ‡∏ó‡∏ß‡∏ô S/E EPO
- [x] ‡∏ó‡∏ß‡∏ô‡∏ß‡∏¥‡∏ò‡∏µ‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ EPO
- [ ] ‡∏ó‡∏ß‡∏ô drug induced hyperkalemia
- [x] ‡∏ó‡∏ß‡∏ô‡∏™‡∏π‡∏ï‡∏£ cockcroft
- [x] ‡∏ó‡∏ß‡∏ô‡∏¢‡∏≤‡∏Å‡∏î‡∏†‡∏π‡∏°‡∏¥
- [ ] ‡∏ó‡∏ß‡∏ô‡∏™‡∏≤‡∏£‡∏≠‡∏≤‡∏´‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏ï‡πâ‡∏≠‡∏á‡πÄ‡∏•‡∏µ‡πà‡∏¢‡∏á‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏õ‡πâ‡∏ô‡πÇ‡∏£‡∏Ñ‡πÑ‡∏ï

# Nephrolithiasis
EAU Guideline on Urolithiasis 2023
- U/S or KUB radiography as standard diagnosis tools
- Pain Relief with NSAIDs (first line) +- Paracetamol
	- Ketorolac (max 90mg/day if < 50 kg then 60 mg/day)
	- NSAIDs no problem in people with normal renal function!
- Opioids
	- No recommendation
- Antispasmodics
	- ‡πÑ‡∏°‡πà‡∏ä‡πà‡∏ß‡∏¢
- Medical Expulsive therapy
	- Alpha-blocker (class effect) for distal ureteral stones > 5mm (‡∏ñ‡πâ‡∏≤‡∏Ç‡∏ô‡∏≤‡∏î‡πÄ‡∏•‡πá‡∏Å‡∏Å‡∏ß‡πà‡∏≤‡∏ô‡∏µ‡πâ benefit ‡πÑ‡∏°‡πà‡∏ä‡∏±‡∏î)
- Oral Chemolysis
	- Uric acid stone -> Sodium bicarbonate ‡πÑ‡∏î‡πâ ‡∏õ‡∏£‡∏±‡∏ö urinary ph ‡πÄ‡∏õ‡πá‡∏ô 7.0-7.2
	- ‡∏ñ‡πâ‡∏≤‡∏Å‡πâ‡∏≠‡∏ô > 8 mm ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ Tamsulosin ‡∏£‡πà‡∏ß‡∏°‡∏î‡πâ‡∏ß‡∏¢‡∏à‡∏∞‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ‡∏¢‡∏≤‡∏ï‡∏±‡∏ß‡πÄ‡∏î‡∏µ‡∏¢‡∏ß
	- Pt monitor ‡∏ï‡∏±‡∏ß‡πÄ‡∏≠‡∏á‡∏î‡πâ‡∏ß‡∏¢ urine dipstick
- Non-pharmacotherapy
	- Extracorporeal shockway lithotripsy
	- Percutaneous nephrolithotomy

# Acute Kidney Injury
- *Quickly* rescue renal
- ‡∏Å‡∏•‡∏∏‡πà‡∏°‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡∏ó‡∏µ‡πà‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡πÑ‡∏ï‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥ ‡πÄ‡∏£‡∏µ‡∏¢‡∏Å‡∏£‡∏ß‡∏° ‡πÜ ‡∏ß‡πà‡∏≤ Nephrotic Syndrome
- Diagnosis #mnemonics 
	- SCr > 0.3 mg/dl ‡πÉ‡∏ô 48 ‡∏ä‡∏°
	- SCr 1.5 times ‡πÉ‡∏ô 7 ‡∏ß‡∏±‡∏ô‡∏´‡∏£‡∏∑‡∏≠‡∏Ñ‡∏≤‡∏î‡∏ß‡πà‡∏≤‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡πÉ‡∏ô 7 ‡∏ß‡∏±‡∏ô
	- Urine Volume < 0.5 ml/kg/hr in 6 hr
- NGAL 2-6 hr, Cystatin C 12 hr, SCr 24 hr
- AKI <= 7 days, AKD < 3 mo + eGFR <  60 and structural abnormalities, CKD > 3 mo + eGFR < 60 and structural abnormalities
- Differentiating cause of AKI
	- Pre-renal
		- Hyalin casts (‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ñ‡∏∂‡∏á dehydration)
		- No urinary WBC, RBC
		- BUN/Scr > 20 (‡∏ö‡πà‡∏á‡∏ö‡∏≠‡∏Å‡∏ß‡πà‡∏≤‡∏°‡∏±‡∏ô‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏õ‡πÉ‡∏ô‡πÑ‡∏ï‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ BUN ‡∏Ñ‡∏±‡πà‡∏á‡πÄ‡∏¢‡∏≠‡∏∞)
		- FE Na < 1%
	- Intrinsic
		- Granular casts + Cellular debris
		- Urinary WBC and RBC 2-4+
		- BUN/Scr 15
		- Fe Na > 2%
	- Post-renal
		- Cellular debris
		- Might have urinary WBC and RBC
		- BUN/Scr 15
- Common Cause of AKI (Drug)
	- Pre-renal
		- NSAIDs, ACEi/ARB, Radiocontrast, Vasopressor
	- Intrinsic
		- ATN
			- Aminoglycosides
			- **Amphotericin B**
			- Tenofovir
			- Rhabdomyolysis  
			- Aminoglycosides  
			- **Cisplatin**  
			- Radiocontrast agent  
			- Methotrexate
		- AIN
			- Drug-hypersensitivity
		- Glomerulonephritis
			- Drug-hypersenstivity -> ‡∏à‡∏∞‡∏û‡∏ö Heavy proteinuria (hypoalbuminemia)
			- Nephrotic syndrome
	- Post-renal
		- [[0 Inbox/Nephrolithiasis\|Nephrolithiasis]]
			- MTX, Sulfadiazine, SMX, Acyclovir, Amoxicillin
- Indication for RRT
	- A (Acid base abnormalities) : Met acidosis esp pH < 7.2
	- Electrolyte Imbalance (Severe hyperkalemia and or hypermagnesemia)
	- Intoxication: Salicylates, Lithium, Methanol, Ethylene glycol, Theophylline, Phenobarbital
	- Overload (Fluid overload esp. in pulmonary edema unersponsive to diuretics)
	- Uremia (uremia or associated complication such as encephalopathy)
- What dialysis to use? Depend on physician
	- Intermittent Hemodialysis IHD (frequently used)
	- CRRT is preferred in hemodynamically stable
- Acid-Base Management | [[0 Inbox/Acid-Base Disorder\|Acid-Base Disorder]]
	- AG = Na - HCO3 - Cl (N: 5-12) ‡∏ñ‡πâ‡∏≤‡∏™‡∏π‡∏á‡∏≠‡∏≤‡∏à Metabolic Acidosis
	- Mild-Moderate (pH > 7.2, HCO3 > 8-12) ‡∏£‡∏±‡∏Å‡∏©‡∏≤‡πÅ‡∏ö‡∏ö [[2 Areas/University/PTHER V/Management of CKD Complications\|Management of CKD Complications]] ‡πÑ‡∏°‡πà‡∏°‡∏µ **role of sodium bicarbonate!!!**
	- **Severe (pH < 7.2, HCO3 < 8-12)** -> may prefer RRT
		- ‡πÉ‡∏ä‡πâ NaHCO3 IV ‡πÇ‡∏î‡∏¢‡πÉ‡∏´‡πâ 1/2 IV (drip in 1-2 min) ‡πÅ‡∏•‡πâ‡∏ß‡∏≠‡∏µ‡∏Å 24 ‡∏ä‡∏°‡πÉ‡∏´‡πâ 1/2 ‡∏ó‡∏µ‡πà‡πÄ‡∏´‡∏•‡∏∑‡∏≠
			- reassess in 2 hrs
			- initial 89.2 - 100 mEq once in 1-2 min
		- **HCO3 Deficit = 0.5 or 0.6 x BW x (HC03 target - HCO3 serum)** #formula 
		- ‡πÇ‡∏î‡∏¢ 7.5% NaHCO3 50 ml ‡∏à‡∏∞‡∏°‡∏µ NaHCO3 44.6 mEq
- Common cause of AKI: THINK SHTOP
	- Sepsis
	- Hypovolemia
	- Toxicity
	- Obstruction
	- Parenchymal Disease
- Treatment:
	- Hydration (if hypo)
		- Holliday Segar (100ml/kg first 10 kg) + 50ml/kg second 10 kg + 20ml/kg remaing wt + ‡∏ô‡πâ‡∏≥‡∏ó‡∏µ‡πà‡πÄ‡∏™‡∏µ‡∏¢‡πÑ‡∏õ
		- Rate: 4 ml/kg/hr first 10 kg + 2 ml/kg/hr second 10 kg + 1 ml/kg/hr remaining wt
		- ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡πÄ‡∏î‡πá‡∏Å < 14 d
	- Loop diuretics (if overload)
		- Furosemide
		- Add Thiazide (to prevent resistance at distal)
		- Add spironolactone (amiloride, tramterene, sprinolactone, to prevent resistant at collecting drug)
- Preventing radiocontrast induced AKI:
	- May give Sodium bicarbonate before and after procedure, or give normal saline
	- No role of N-acetylcysteine
- Glycemic Goal
	- 140-180 mg/dl during AKI
	- critically ill: > 180 mg/dl
- AKI Staging  #mnemonics 

| Stage   | Urine Output                            | KDIGO 2012 SCr (Revised personal opinion)                        |
| ------- | --------------------------------------- | ---------------------------------------------------------------- |
| Stage 1 | < 0.5 ml/kg/hr more than 6 hr           | SCr > 0.3 mg/dl in 48 hrs OR 1.5 times - 1.9 times from baseline |
| Stage 2 | < 0.5 ml/kg/hr more than 12 hr          | 2.0 - 2.99 times from baseline                                   |
| Stage 3 | < 0.3 ml/kg/hr (Anuria) more than 12 hr | > 3 times from baseline <br>OR RTT<br>OR SCr > 4.0               |

# Chronic Kidney Disease
- Definition: eGFR < 60 and Structural Damage, more than 3 months
- Complication of late stage CKD
	- Hypocalemia
	- Hyperphosphatemia
	- HyperPTH
	- Hyperpotassium
	- Leg Cramping (Magnesium ‡∏°‡∏±‡∏ô‡∏≠‡∏≠‡∏Å)
	- Anemia -> Fatigue
	- Nocturia
	- Metabolic Acidosis
- [[2 Areas/University/Hypertension\|Hypertension]]
	- Goal < 120 mmHg ‡∏û‡∏ö‡∏ß‡πà‡∏≤‡∏•‡∏î all-cause mortality ‡πÅ‡∏ï‡πà‡πÑ‡∏°‡πà‡∏•‡∏î CVD Event
		- ‡∏≠‡∏±‡∏ô‡πÄ‡∏î‡∏¥‡∏° KDIGO 2012 <140
		- ‡∏Ç‡∏≠‡∏á‡πÑ‡∏ó‡∏¢ 2565 ‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥ <140/90
		- **‡∏ó‡∏±‡πâ‡∏á‡πÑ‡∏ó‡∏¢‡∏ó‡∏±‡πâ‡∏á KDIGO ‡πÄ‡∏Å‡πà‡∏≤:** ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å Kidney Transplant or AER > 30 ‡πÉ‡∏´‡πâ **SBP < 130**
	- Start RASi ‡∏´‡∏≤‡∏Å AER > 300 ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏°‡∏µ‡πÄ‡∏ö‡∏≤‡∏´‡∏ß‡∏≤‡∏ô‡∏£‡πà‡∏ß‡∏°‡∏î‡πâ‡∏ß‡∏¢ 30-300 ‡∏Å‡πá‡∏Ñ‡∏ß‡∏£‡πÄ‡∏£‡∏¥‡πà‡∏°‡πÅ‡∏•‡πâ‡∏ß
		- ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å 30-300 ‡∏¢‡∏±‡∏á‡πÑ‡∏°‡πà‡∏°‡∏µ‡πÄ‡∏ö‡∏≤‡∏´‡∏ß‡∏≤‡∏ô ‡∏≠‡∏±‡∏ô‡∏ô‡∏µ‡πâ‡πÅ‡∏Ñ‡πà‡∏£‡∏∞‡∏î‡∏±‡∏ö suggestion
- [[0 Inbox/Fluid and Electrolyte Disorder#Hyperkalemia\|Hyperkalemia]]
	- Sodium polystyrene sulfonate
	- Calcium polystyrene sulfonate
	- TBW ‡πÄ‡∏ß‡∏•‡∏≤‡∏Ñ‡∏≥‡∏ô‡∏ß‡∏ì‡πÉ‡∏´‡πâ‡∏ä‡∏≤‡∏¢ 0.6 ‡∏´‡∏ç‡∏¥‡∏á 0.5
- [[2 Areas/University/PTHER II/Anemia (PTHER II)\|Anemia (PTHER II)]] or [[2 Areas/University/Anemia (CC)\|Anemia (CC)]]
	- Hb < 13 in male / < 12 in female
	- Normocytic anemia
	- Goal: TSAT > 20% ‡πÅ‡∏•‡∏∞ Ferritin > 100 ng/ml (hemodialysis > 200 ng/dl)
	- ‡πÄ‡∏Å‡∏ì‡∏ë‡πå IV Iron: Ferritin < 500 ‡πÅ‡∏•‡∏∞ TSAT < 30%
	- ‡∏ñ‡πâ‡∏≤‡∏Ç‡∏≤‡∏î‡∏ó‡∏±‡πâ‡∏á ferritin & TSAT = absolute iron def
	- ‡∏ñ‡πâ‡∏≤‡∏Ç‡∏≤‡∏î‡πÅ‡∏Ñ‡πà TSAT (‡∏°‡∏µ‡πÉ‡∏ô‡∏Ñ‡∏•‡∏±‡∏á‡πÅ‡∏ï‡πà‡πÄ‡∏≠‡∏≤‡∏°‡∏≤‡πÉ‡∏ä‡πâ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ) = functional def
	- Oral Iron
		- Elemental iron: Ferrous fumarate > Ferrous sulfate > Ferrous gluconate #mnemonics 
			- Ferrous fumarate -> 33%
			- Ferrous sulfate -> 20%
			- Ferrous gluconate -> 11.6%
		- iron ‡∏à‡∏∞‡πÉ‡∏´‡πâ **elemental 200mg/day**
		- vitC ‡πÄ‡∏û‡∏¥‡πà‡∏°‡∏Å‡∏≤‡∏£‡∏î‡∏π‡∏î‡∏ã‡∏∂‡∏° ‡πÉ‡∏´‡πâ‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏ô 300 mg/d
		- ‡πÑ‡∏°‡πà‡πÉ‡∏ä‡πâ‡πÅ‡∏ö‡∏ö enteric ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏î‡∏π‡∏î‡∏ã‡∏∂‡∏°‡πÑ‡∏î‡πâ‡πÉ‡∏ô‡∏Å‡∏£‡∏î
	- EPO
		- ‡∏õ‡∏Å‡∏ï‡∏¥‡∏à‡∏∞‡πÉ‡∏´‡πâ‡πÅ‡∏ö‡∏ö SC ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏î‡∏µ‡∏Å‡∏ß‡πà‡∏≤ IV --> ‡πÉ‡∏ä‡πâ‡∏Ç‡∏ô‡∏≤‡∏î‡∏¢‡∏≤‡∏ï‡πà‡∏≥‡∏Å‡∏ß‡πà‡∏≤ ‡πÅ‡∏•‡∏∞‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Ç‡πâ‡∏≤ target ‡πÑ‡∏î‡πâ‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô‡∏Å‡∏±‡∏ö IV
		- ‡∏õ‡∏Å‡∏ï‡∏¥‡∏à‡∏∞‡πÉ‡∏´‡πâ‡πÅ‡∏ö‡πà‡∏á‡πÄ‡∏õ‡πá‡∏ô 2-3 ‡∏Ñ‡∏£‡∏±‡πâ‡∏á‡∏ï‡πà‡∏≠‡∏™‡∏±‡∏õ‡∏î‡∏≤‡∏´‡πå ‡∏ñ‡πâ‡∏≤ SC: 80-120 unit/kg/wk 2-3 doses/week
			- criteria for EPO
				- **if Hb > 10 mg/dl ‡πÑ‡∏°‡πà‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏¢‡∏≤**
				- ‡πÄ‡∏õ‡πâ‡∏≤‡∏´‡∏°‡∏≤‡∏¢ **11.5 mg/dl** ‡πÑ‡∏°‡πà‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤ 13 mg/dl
				- onset 2-4 weeks full effect
				- SC > IV
				- dose ‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£ correct ‡∏à‡∏∞‡∏™‡∏π‡∏á‡∏Å‡∏ß‡πà‡∏≤ maintenance ‡∏õ‡∏£‡∏∞‡∏°‡∏≤‡∏ì 20-30%
			- EPO ADR
				- Hyperkalemia
				- **Pure Red Cell Anemia**
				- Hypertension
- [[2 Areas/University/Dyslipidemia\|Dyslipidemia]]
- [[2 Areas/University/Diuretics\|Diuretics]] (Hypervolemia)
	- ‡πÅ‡∏£‡∏Å‡πÄ‡∏£‡∏¥‡πà‡∏°‡πÉ‡∏ä‡πâ **Thiazide 25-50 mg od or bid** (higher dose than [[2 Areas/University/Hypertension\|Hypertension]])
	- ‡πÉ‡∏ä‡πâ‡πÄ‡∏û‡∏∑‡πà‡∏≠‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô‡∏Å‡∏≤‡∏£‡πÑ‡∏õ‡∏Å‡∏î‡∏´‡∏±‡∏ß‡πÉ‡∏à‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ ‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô‡∏Å‡∏≤‡∏£‡πÄ‡∏Å‡∏¥‡∏î volume overload 
	- **‡πÉ‡∏ä‡πâ Furosemide ‡∏ñ‡πâ‡∏≤ eGFR < 30**
	- Furosemide ‡∏£‡∏ö‡∏Å‡∏ß‡∏ô electrolyte imbalance > thiazide ‡πÅ‡∏ï‡πà metabolic effects ‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤!
	- Thiazide-like = Indapamide, chlorthalidone ‡πÅ‡∏Ñ‡πà‡∏°‡∏µ metabolic S/E ‡∏ô‡πâ‡∏≠‡∏¢‡∏Å‡∏ß‡πà‡∏≤‡πÄ‡∏â‡∏¢ ‡πÜ
- Serum Phosphate
	- N: 2.7-4.6
	- **‡∏ñ‡πâ‡∏≤ Ca x P ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 55** ‡πÉ‡∏´‡πâ‡∏£‡∏±‡∏Å‡∏©‡∏≤‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á calcification
	- First Line = Calcium carbonate (max elemental 1500mg/day) or Sevelamer carbonate
	- ‡πÉ‡∏ä‡πâ Phosphate Binder
		- Antacid
			- ‡∏ñ‡πâ‡∏≤‡∏°‡∏µ Aluminum ‡∏à‡∏∞‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î Blood/Brain/Bone complication ‡πÑ‡∏î‡πâ ‡πÑ‡∏î‡πâ‡πÅ‡∏Å‡πà microcytic anemia, encephalopathy, adynamic bone disease
		- Resins
			- Sevelamer carbonate ‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á‡πÄ‡∏Ñ‡∏µ‡πâ‡∏¢‡∏ß ‡∏≠‡∏≤‡∏à‡∏à‡∏±‡∏ö bile acid ‡∏î‡πâ‡∏ß‡∏¢ ‡∏à‡∏±‡∏ö‡∏¢‡∏≤‡∏≠‡∏∑‡πà‡∏ô‡∏î‡πâ‡∏ß‡∏¢ ‡∏¢‡∏≤‡∏≠‡∏∑‡πà‡∏ô‡∏Ñ‡∏ß‡∏£‡∏ó‡∏≤‡∏ô‡∏Å‡πà‡∏≠‡∏ô sevel 1‡∏ä‡∏° / ‡∏´‡∏•‡∏±‡∏á sevel 3‡∏ä‡∏°
			- Lathanum carbonate (‡πÄ‡∏Ñ‡∏µ‡πâ‡∏¢‡∏ß) ‡∏£‡∏±‡∏Å‡πÄ‡∏î‡∏µ‡∏¢‡∏ß‡πÉ‡∏à‡πÄ‡∏î‡∏µ‡∏¢‡∏ß ‡πÑ‡∏°‡πà‡∏à‡∏±‡∏ö‡∏¢‡∏≤‡∏≠‡∏∑‡πà‡∏ô
	- Calcium salts
		- Calcium carbonate and acetate ‡πÉ‡∏´‡πâ efficacy ‡πÄ‡∏ó‡πà‡∏≤‡∏Å‡∏±‡∏ô
			- Calcium acetate ‡πÅ‡∏û‡∏á‡∏Å‡∏ß‡πà‡∏≤
			- Calcium carbonate ‡πÉ‡∏´‡πâ elemental ‡πÄ‡∏¢‡∏≠‡∏∞‡∏Å‡∏ß‡πà‡∏≤
- Serum HCO3-
	- Keep > 22 mEq/L (N: 22-28)
	- KDIGO ‡πÑ‡∏°‡πà‡∏°‡∏µ‡πÄ‡∏Å‡∏ì‡∏ë‡πå‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏¢‡∏≤‡∏ó‡∏µ‡πà‡πÅ‡∏ô‡πà‡∏ô‡∏≠‡∏ô ‡πÅ‡∏ï‡πà NICE ‡πÉ‡∏´‡πâ‡πÄ‡∏£‡∏¥‡πà‡∏°‡πÄ‡∏°‡∏∑‡πà‡∏≠ < 20 mEq/L
- [[2 Areas/University/Diabetes mellitus\|Diabetes mellitus]]
	- T2DM and T1DM should be screened for CKD
	- HbA1C q3month if uncontrolled, q6mo if controlled
	- Target: 6.5-8 individualize by the patient factors
	- Update to KDIGO Consensus with ADA (‡∏à‡∏≤‡∏Å‡∏ó‡∏µ‡πà‡∏ó‡∏≥ AC @ [[4 Archives/University Clerkship/04 ‡πÄ‡∏à‡∏£‡∏¥‡∏ç‡∏Å‡∏£‡∏∏‡∏á‡∏õ‡∏£‡∏∞‡∏ä‡∏≤‡∏£‡∏±‡∏Å‡∏©‡πå\|04 ‡πÄ‡∏à‡∏£‡∏¥‡∏ç‡∏Å‡∏£‡∏∏‡∏á‡∏õ‡∏£‡∏∞‡∏ä‡∏≤‡∏£‡∏±‡∏Å‡∏©‡πå]])
		- Metformin
			- ‡∏•‡∏î‡πÄ‡∏´‡∏•‡∏∑‡∏≠ 1000 @ eGFR < 45 ‡πÅ‡∏•‡∏∞‡πÑ‡∏°‡πà‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ‡∏ñ‡πâ‡∏≤ <30
		- Insulin
			- eGFR < 45 ‡πÉ‡∏´‡πâ‡∏õ‡∏£‡∏±‡∏ö‡∏Ç‡∏ô‡∏≤‡∏î‡∏¢‡∏≤‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏£‡∏∞‡∏°‡∏±‡∏î‡∏£‡∏∞‡∏ß‡∏±‡∏á
		- Sulfonylureas
			- Glipizide ‡πÉ‡∏´‡πâ‡πÄ‡∏£‡∏¥‡πà‡∏° 2.5 mg od ‡∏û‡∏≠‡∏´‡∏•‡∏±‡∏á eGFR < 45
		- a-glucosidase inhibiotrs
			- ‡∏ñ‡πâ‡∏≤ eGFR < 30 ‡πÑ‡∏°‡πà‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ Acarbose
		- SGLT2-i ‡∏ñ‡πâ‡∏≤‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏°‡∏≤‡πÅ‡∏•‡πâ‡∏ß‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏´‡∏¢‡∏∏‡∏î ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏à‡∏∞‡∏û‡∏∂‡πà‡∏á‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏Å‡πá‡πÄ‡∏Å‡∏ì‡∏ë‡πå‡∏ï‡∏≤‡∏°‡∏ô‡∏µ‡πâ ‡∏™‡πà‡∏ß‡∏ô max dose ‡πÉ‡∏´‡πâ‡∏•‡∏î‡πÄ‡∏´‡∏•‡∏∑‡∏≠‡∏ï‡∏≤‡∏°‡∏ô‡∏µ‡πâ‡∏´‡∏•‡∏±‡∏á eGFR < 45
			- Canagliflozin 100-300 mg od (max 100 mg) 
			  Initiation not recommend ed if eGFR < 30
			- Dapagliflozin 5-10 mg od (max 10 mg) 
			  Initiation not recommend ed if eGFR < 25
			- Empagliflozin 10-25 mg od (max 10 mg) 
			  Initiation not recommend ed if eGFR < 20
		- GLP-1 RA
			- Dulaglutide, Liraglutide, Semaglutide ‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏õ‡∏£‡∏±‡∏ö‡∏ï‡∏≤‡∏°‡πÑ‡∏ï‡πÄ‡∏•‡∏¢‡∏¢‡∏Å‡πÄ‡∏ß‡πâ‡∏ô Lixisenatide
			- ‡πÉ‡∏ô‡∏Å‡∏£‡∏ì‡∏µ‡∏Ç‡∏≠‡∏á Semaglutide oral ‡∏à‡∏∞‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏ß‡∏±‡∏î‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Å‡∏±‡∏ö renal ‡∏à‡∏∂‡∏á‡πÑ‡∏°‡πà‡∏°‡∏µ‡∏Ñ‡∏≥‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥‡∏ï‡∏£‡∏á‡∏ô‡∏µ‡πâ
		- DPP-IV
			- Linagliptin ‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡∏±‡∏ß‡πÄ‡∏î‡∏µ‡∏¢‡∏ß‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏õ‡∏£‡∏±‡∏ö‡∏ï‡∏≤‡∏°‡πÑ‡∏ï‡πÄ‡∏•‡∏¢
- Secondary Hyperparathyroidism
	- ‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å Hypocal, Hyperphos
	- Hypocal -> ‡∏Å‡∏£‡∏∞‡∏ï‡∏∏‡πâ‡∏ô PTH
	- Hypocal ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÑ‡∏ï‡∏û‡∏±‡∏á VitD ‡∏Å‡πá‡∏´‡∏≤‡∏¢‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÑ‡∏ï‡∏û‡∏±‡∏á
	- ‡∏ï‡∏±‡∏ö -> 25(OH)D (Calcidiol) -> ‡πÑ‡∏ï -> **1,25(OH)2D (Calcitriol)**
	- ‡πÅ‡∏Å‡πâ‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ Calcitriol or **Vitamin D Analog** (Paricalcitol, Doxercalciferol) ‡πÉ‡∏´‡πâ‡πÄ‡∏õ‡πá‡∏ô od ‡∏ô‡∏∞‡πÑ‡∏°‡πà‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô [[2 Areas/University/Osteoporosis (OP)\|Osteoporosis (OP)]] ([[0 Inbox/Musculoskeletal Disorder (Summary)#Osteoporosis\|Musculoskeletal Disorder (Summary)#Osteoporosis]]!!! ‡∏´‡∏£‡∏∑‡∏≠ Calcimemaetic Agent ‡πÄ‡∏ä‡πà‡∏ô Cinacalcet, Ethecalcetide
	- PTHER Handbook: Ergocalceferol / Cholecalciferol/ Calcifediol
	- ‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏≠‡∏á Routinely **‡πÅ‡∏Å‡πâ PTH (KDIGO 2017) ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤ progressive ‡πÉ‡∏´‡πâ‡πÅ‡∏Å‡πâ**
- Lifestyle Modification
	- Protein < 0.8 g/kg/day ‡∏´‡∏≤‡∏Å eGFR < 30
	- Protein < 1.3 g/kg/day ‡∏´‡∏≤‡∏Å Risk of CKD Progression
	- ‡πÉ‡∏´‡πâ‡πÇ‡∏õ‡∏£‡∏ï‡∏µ‡∏ô 1.0 g/kg/day ‡∏´‡∏≤‡∏Å‡∏ó‡∏≥ HD or PD
	- Sodium < 2 g (NaCl < 5 g) ‡πÇ‡∏î‡∏¢ 1 tsp of salt = 5 g NaCl (‡πÉ‡∏ô NaCl 1 g ‡∏õ‡∏£‡∏∞‡∏Å‡∏≠‡∏ö‡πÑ‡∏õ‡∏î‡πâ‡∏ß‡∏¢ 40% Na ‡πÅ‡∏•‡∏∞ 60% Cl)
